Nextech Invest

Type

Venture Capital

Status

Active

Location

Zurich, Switzerland

Total investments

88

Average round size

92M

Portfolio companies

59

Rounds per year

3.38

Lead investments

19

Follow on index

0.33

Exits

29

Stages of investment
Early Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharmaBioinformatics

Summary

Nextech Invest appeared to be the VC, which was created in 1998. The fund was located in Europe if to be more exact in Switzerland. The main department of described VC is located in the Zu00fcrich.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Nextech Invest, startups are often financed by Third Rock Ventures, OrbiMed, 5AM Ventures. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Casdin Capital, The Column Group. In the next rounds fund is usually obtained by Future Capital, Wellington Management, The Column Group.

Besides them, we counted 4 critical employees of this fund in our database.

The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Vividion Therapeutics, TetraLogic Pharmaceuticals, Kura Oncology Among the most successful fund investment fields, there are Clinical Trials, Medical Device. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.

Comparing to the other companies, this Nextech Invest performs on 35 percentage points more the average number of lead investments. The usual things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The higher amount of exits for fund were in 2015. Speaking about the real fund results, this VC is 8 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2019.

Show more

Investor highlights

Industry focus
Medtech
Geo focus
AlbaniaAustriaBelgiumBosnia and HerzegovinaBulgaria Show 37 more

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
88
Lead investments
19
Exits
29
Rounds per year
3.38
Follow on index
0.33
Investments by industry
  • Biotechnology (80)
  • Health Care (49)
  • Therapeutics (38)
  • Pharmaceutical (26)
  • Medical (25)
  • Show 13 more
Investments by region
  • United States (76)
  • Germany (4)
  • United Kingdom (2)
  • China (1)
  • Canada (1)
  • Show 1 more
Peak activity year
2021
Number of Unicorns
1
Number of Decacorns
1
Number of Minotaurs
4

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
8
Avg. valuation at time of investment
47M
Group Appearance index
0.97
Avg. company exit year
9
Avg. multiplicator
1.14
Strategy success index
0.90

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Delphia Therapeutics 02 May 2024 Early Stage Venture 67M
CARGO Therapeutics 01 Mar 2023 Biotechnology, Medical, Therapeutics Early Stage Venture 200M United States, California, Palo Alto

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.